NCT01899729View on ClinicalTrials.gov

A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Plaque Psoriasis
Interventions
DRUG

IMO-8400 Regimen 1

IMO-8400 0.075 mg/kg q wk x 12 wk by subcutaneous injection

DRUG

IMO-8400 Regimen 2

IMO-8400 0.15 mg/kg q wk x 12 wk by subcutaneous injection

DRUG

IMO-8400 Regimen 3

IMO-8400 0.3 mg/kg q wk x 12 wk by subcutaneous injection

DRUG

Saline Placebo

Saline q wk x 12 wk by subcutaneous injection

DRUG

IMO-8400 Regimen 4

IMO-8400 0.6 mg/kg q wk x 12 wk by subcutaneous injection

Trial Locations (1)

Unknown

Centre for Human Drug Research, Leiden

Sponsors
All Listed Sponsors
lead

Idera Pharmaceuticals, Inc.

INDUSTRY

NCT01899729 - A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter